We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+5.42%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$6.42M
(-4.4%)
Cap. Flow
-$4.09M
Cap. Flow % of AUM
Cap. Flow %
-2.97%
Top 10 Holdings %
Top 10 Hldgs %
92.68%
Holding
18
New
–
Increased
–
Reduced
2
Closed
1
Avg Time Held
1.7
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
1.7
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cymabay Therapeutics
CBAY
|
+$3.38M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$390K |
| 3 |
INNL
Innocoll Holdings
INNL
|
+$322K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q4 2017 Portfolio in Review
As of Q4 2017, Abingworth held 18 positions worth $138M, down 4.4% from $144M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Abingworth's Q4 2017 filing shows 2 reduced and 1 closed positions. The largest sale was Cymabay Therapeutics, an estimated $3.38M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Abingworth's biggest Q4 2017 reduction was Cymabay Therapeutics, cutting an estimated $3.38M.
- Abingworth fully exited Innocoll Holdings in Q4 2017, selling an estimated $322K.
- Abingworth's ten largest holdings make up 93% of its $138M portfolio in Q4 2017.
- Abingworth opened 0 new positions and closed 1 in Q4 2017.
- Abingworth's portfolio value fell 4.4% quarter-over-quarter to $138M.
Based on Abingworth's 13F filing for Q4 2017, filed 14 Feb 2018.